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Abstract
Background: Activation of voltage-gated potassium channels of the Kv7 (KCNQ) family reduces cellular excitability. These
channels are therefore attractive targets for treatment of diseases characterized by hyperexcitability, such as epilepsy,
migraine and neuropathic pain. Retigabine, which opens Kv7.2-5, is now in clinical trial phase III for the treatment of partial
onset seizures. One of the main obstacles in developing Kv7 channel active drugs has been to identify compounds that can
discriminate between the neuronal subtypes, a feature that could help diminish side effects and increase the potential of
drugs for particular indications.
Methodology/Principal Findings: In the present study we have made a thorough investigation of the Bristol-Myers Squibb
compound (S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide [(S)-2]
on human Kv7.1-5 channels expressed in Xenopus laevis oocytes. We found that the compound was a weak inhibitor of
Kv7.1. In contrast, (S)-2 efficiently opened Kv7.2-5 by producing hyperpolarizing shifts in the voltage-dependence of
activation and enhancing the maximal current amplitude. Further, it reduced inactivation, accelerated activation kinetics
and slowed deactivation kinetics. The mechanisms of action varied between the subtypes. The enhancing effects of (S)-2
were critically dependent on a tryptophan residue in S5 also known to be crucial for the effects of retigabine, (S)-1 and BMS-
204352. However, while (S)-2 did not at all affect a mutant Kv7.4 with a leucine in this position (Kv7.4-W242L), a Kv7.2 with
the same mutation (Kv7.2-W236L) was inhibited by the compound, showing that (S)-2 displays a subtype-selective
interaction with in the Kv7 family.
Conclusions/Significance: These results offer further insight into pharmacological activation of Kv7 channels, add to the
understanding of small molecule interactions with the channels and may contribute to the design of subtype selective
modulators.
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Introduction
Voltage-gated potassium (Kv) channels of the Kv7 (KCNQ)
family are important regulators of neuronal excitability. Five
members, Kv7.1-5, have been reported so far. Kv7.1 is best known
foritsexpressionincardiactissuewhereitassembleswithKCNE1to
conduct the IKs current [1,2]. The other four proteins are reported
as the neuronal Kv7 channels (although they are also found in other
tissues [3,4]) and constitute the molecular correlates of the M-
current [5,6]. This current is primarily due to heteromeric
assemblies of Kv7.2 and Kv7.3 [7], but also Kv7.4 and Kv7.5
show M-current characteristics [8–11]. All subtypes share the
general structure of Kv channels with four subunits assembling into
functional tetramers, either homo- or heteromeric. Each subunit
comprisessixtransmembranehelices,S1-S6,and hasa poreforming
domain, which is formed by a P-loop between the fifth and sixth
helix. The fourth helix forms the voltage sensor that contains several
arginine residues and is therefore strongly positively charged [6].
Neuronal Kv7 channels activate at membrane potentials that
are below the threshold required for generation of an action
potential. They therefore allow for potassium flux that opposes
depolarization, hence their activation will make the neuron less
excitable. This makes them particularly interesting as targets for
treatment of CNS diseases linked to hyperexcitability, including
epilepsy, neuropathic pain and migraine. In addition, Kv7.2 and
Kv7.4 are expressed in dopaminergic neurons of the midbrain,
where they modulate the release of dopamine [12–15]. This has
opened the possibility of Kv7 channels as a target for treatment of
diseases characterized by dysfunction in the dopaminergic system,
such as ADHD, drug abuse, and schizophrenia [15].
Negative and positive modulators of the M-channels have
existed even before the molecular correlates were identified and
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8251cloned. Retigabine, the best described of these, is now in clinical
trials phase III for the treatment of partial-onset seizures.
Retigabine enhances the current through all neuronal homo-
and heteromeric Kv7 channels, but not the cardiac Kv7.1. It
induces a large hyperpolarizing shift in the voltage-dependence of
activation of the channels, accelerates the activation and slows the
deactivation kinetics [16–18]. Though several new classes of
modulators have emerged since the cloning of Kv7 channels, there
is still a lack of truly subtype selective compounds that can
discriminate between the neuronal Kv7 channels. It is therefore
still impossible to study the contribution of each individual subtype
to the in vivo effect of e.g. retigabine. This knowledge would be
valuable for identification of the ideal subtype to target for each
indication.
In the present study we thoroughly investigated the effects of the
Bristol-Myers Squibb compound (S)-N-[1-(4-Cyclopropylmethyl-
3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-
acrylamide [(S)-2] (fig. 1) on human Kv7.1-5 channels. The
compound has previously been reported as a potent and efficacious
Kv7.2 opener with significant activity in reducing hyperexcitability
in rat hippocampal slices [19]. We show that (S)-2 is an activator of
all neuronal Kv7 channels, but an inhibitor of Kv7.1. Further-
more, (S)-2 binds to the ‘‘retigabine-binding site’’, however, while
having no effect on a Kv7.4 channel with the critical mutation that
renders the channel retigabine insensitive, (S)-2 inhibits a Kv7.2
channel with the same mutation, thereby revealing a subtype
selectivity of modulation and interaction. In addition, our work
indicates that in contrast to retigabine, (S)-2 is not dependent on
being bound to all four subunits simultaneously for its enhancing




The care of Xenopus laevis and the oocyte extraction procedure
were performed according to national guidelines and approved by
the Danish Animal Experiments Inspectorate.
Molecular Biology
The point mutations W236L in Kv7.2 and G285S in Kv7.4
were introduced using mutated oligonucleotide extension (Pfu-
Turbo Polymerase, Stratagene, La Jolla, CA, USA) from a plasmid
template harboring the cDNA of interest, digested with DpnI
(Fermentas, St. Leon, Germany) and transformed into E.coli XL1
Blue cells. The construct was verified by complete DNA
sequencing of the cDNA insert. The Kv7.4-W242L mutant was
a kind gift from Bo Hjorth Bentzen [20]. cRNA for injection was
prepared from linearized human wild-type (WT) Kv7.1-5 and
mutant Kv7.2 and Kv7.4 in pGEM-HE vectors using the T7 m-
Message Machine kit (Ambion, Austin, TX, USA) according to the
manufacturer’s instructions. RNA concentrations were quantified
using UV spectroscopy and RNA quality was checked by gel
electrophoresis.
Expression in Xenopus laevis Oocytes
Female Xenopus laevis were anaesthetized by immersion in a
0.4% (w/v) solution of 3-aminobenzoic acid ethyl ester (Sigma, St.
Louis, Missouri, USA) for 15–20 min. Ovarian lobes were cut off
through a small abdominal incision and subsequently defollicu-
lated by enzymatic treatment with 0.5 mg/mL collagenase type IA
(Sigma, St. Louis, MO, USA) in OR2 solution (in mM: 82.5 NaCl,
2 KCl, 1 MgCl2, 5 HEPES, pH 7.4) for 3 hours. Oocytes were
then kept in Modified Barth’s Saline (in mM: 88 NaCl, 1 KCl, 2.4
NaHCO3, 0.41 CaCl2, 0.82 MgSO4, 0.3 Ca(NO3)2, 15 HEPES,
pH 7.4 suppl. with 100 U/mL penicillin and 100 mg/mL
streptomycin) at 18uC until injection. cRNA was injected using a
Nanoliter Injector (World Precision Instruments, Sarasota,
Florida, USA). For Kv7.1 between 2 and 10 ng of cRNA was
injected, for Kv7.2, Kv7.2-W236L and Kv7.5 10–25 ng was
injected and for Kv7.4 and Kv7.4-W242L 3–6 ng was injected.
For co-expression of Kv7.2 and Kv7.3 2 ng of each was injected.
The oocytes were kept in Modified Barth’s Saline at 18uC and
currents were recorded after 2–7 days.
Electrophysiology. Kv7 currents in Xenopus laevis oocytes
were recorded using two-electrode voltage-clamp. The recordings
were performed at room temperature in Ringer buffer (in mM:
115 NaCl, 2.5 KCl, 1.8 CaCl2, 0.1 MgCl2, 10 HEPES, pH 7.4)
using an Axon GeneClamp 500B two-electrode voltage-clamp
amplifier (Axon Instruments Inc., Union City, CA, USA) and a
Digidata 1440A digitizer (Axon Instruments). The oocytes were
placed in homemade perfusion chambers connected to a
continuous flow system. Recording electrodes were pulled from
filamented borosilicate glass capillaries (type GC150TF-10,
Harvard Apparatus, Kent, U.K.) on a horizontal Flaming/
Brown Model P-97 micropipette puller (Sutter Instrument
Company, Novato, California, USA) and filled with 1 M KCl.
The electrodes had a resistance of 0.5–2.5 MV. All experiments
were performed on minimum two batches of oocytes.
Rubidium Flux Assay. Chinese hamster ovary (CHO) cells
were transiently transfected with human Kv7.2, Kv7.2-W236L
or Kv7.4 cDNA inserted into pcDNA3 vectors using
Lipofectamine2000 and FuGENE 6, plated in 96 wells plates
and incubated with 1 mCi/mL
86Rb overnight. The following day
the cells were washed twice with assay buffer (HBSS with 20 mM
HEPES, pH 7.4) and stimulated with (S)-2 diluted in stimulation
buffer (assay buffer with 15 or 30 mM KCl for assessing activation
or inhibition, respectively) for 30 min at 37uC. The supernatant
was transferred to a new 96 well plate and added 100 mL
scintillation fluid (Optiphase ‘‘Supermix’’, PerkinElmer). The cells
were washed, added 50 mL of assay buffer and scintillation fluid
and incubated at room temperature at a shaker for 15 min to lyse
the cells. The plates were finally counted on a liquid scintillation
counter (Wallac MicroBetaH TriLux, PerkinElmer). Raw data was
obtained as counts per minute (cpm) and are presented as cpm in
the supernatant divided with total counts (supernatant+cell pellet)
normalized using the equation (X-min)/(max-min)*100 where min
and max are the cpmsup/cpmtotal ratios obtained when stimulating
with 15 and 100 mM KCl, respectively (for experiments with
Kv7.2 and Kv7.4). Data from experiments with Kv7.2-W236L are
normalized by dividing with the cpmsup/cpmtotal ratio obtained
when stimulating with 30 mM KCl.
Figure 1. Chemical structure of (S)-2.
doi:10.1371/journal.pone.0008251.g001
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(S)-2 was dissolved in dimethyl sulfoxide to obtain a concentrated
stock solution. On the day of experiments the stock solution was
thawed and diluted in Ringer buffer to the final concentrations. A
concentration of 10 mM (S)-2 was used unless indicated otherwise.
The final dimethyl sulfoxide concentration never exceeded 0.15%
for experiments on oocytes and 1% for experiments on CHO cells.
(S)-2 was synthesized in-house at H. Lundbeck A/S, Valby,
Denmark, according to literature methods [19].
Statistical Analysis and Curve Fitting
Data was acquired using pCLAMP 10.2 software (Molecular
Devices, CA, USA) and analyzed using pCLAMP 10.2 and
GraphPad Prism 4.0 (GraphPad Software Inc., CA, USA).
The voltage-dependence of activation was determined from tail
current analysis using the current measured immediately after the
transient capacitative current after stepping to 2120 mV from
potentials between 2100 mV and +60 mV. Data was normalized
to extend from 0–1 and the tail current-voltage relationship was
fitted to the Boltzmann equation:
IV ðÞ ~
Imax{Imin
1zexp V{V0:5 ðÞ k ½ 
zImin ðEquation1Þ
where Imax is the maximum tail current, Imin is the minimum tail
current, V0.5 is the potential for half maximal activation and k is
the slope factor. A V0.5 was calculated for each individual
experiment and statistical significance was estimated by two-tailed
Student’s t-test.
Activation kinetics was determined by eliciting currents from a
holding potential of 280 mV to potentials between 2100 mV and
+60 mV of 5 s duration. An F test was used to assess whether
single or double exponential functions gave the highest R
2 value.
For Kv7.2 and Kv7.2-W236L current traces were best fitted to a
double exponential function:








where I(t) is the current at time t, Ifast and Islow are the current
amplitudes at infinite times, and tfast and tslow are the time
constants of the fast and slow components, respectively.
The current traces for Kv7.4 were best fitted to a single
exponential function:





where I(t) is the current at time t, I0 is the peak current and t is the
activation time constant.
For Kv7.2 and Kv7.2-W236L current traces between 240 mV
and +40 mV were used fitting while for Kv7.4 current traces
between 220 mV and +60 mV were used.
For investigation of deactivation kinetics oocytes were held for
5sa t+40 mV before stepping to potentials between 2110 mV
and 280 mV for 6 s. Tail current traces were best fitted to a
double exponential function (Eq. 2). For data concerning
activation and deactivation kinetics statistical significance was
determined by two-way ANOVA followed by Bonferroni post-tests
(if the overall P-value of the drug factor was less than 0.05). Before
the statistical analyses of the fast component of the activation for
Kv7.2 and Kv7.2-W236L the measured time constants were log-
transformed to meet the assumption of normality. For traces fitted
to double exponential functions only those where the sum of Ifast
and Islow equalled the peak current were included in the analysis.
Dose-response curves from electrophysiological experiments
were made by plotting the increase in steady state current at 0 mV
expressed in percentages as a function of drug concentration. The
data were then analyzed by non-linear regression and fitted to the
equation for sigmoidal dose-response with variable slope:
Y~R1z
R2{R1
1z10^ logEC50{X ðÞ |nH ðÞ
ðEquation4Þ
where R1 is the initial response, R2 is the maximum response, X is
the logarithm of the drug concentration and nH is the slope (Hill
coefficient) of the curve.
To determine the EC50 or IC50 values from Rubidium flux
experiments data from different test days were pooled, analyzed by
non-linear regression and fitted to equation 4 (in the case of Kv7.2-
W236L the parameter EC50 is replaced with IC50). pEC50 values
and Hill slopes were calculated for each individual experiment and
statistical significance was estimated by two-tailed Student’s t-test.
For analysis of the remaining data statistical significance was
determined by two-tailed Student’s t-test if single comparisons
were made and by two-way ANOVA followed by Bonferroni post-
tests if multiple comparisons were made. Statistical analyses were
carried out using GraphPad Prism 4.0. P,0.05 was accepted for
statistical difference. All values are shown as mean6S.E.M.
Results
Effect of (S)-2 on Kv7.1-5 Current Amplitude
The effect of (S)-2 on Kv7 channels expressed in Xenopus laevis
oocytes was studied using two-electrode voltage-clamp. The
channels were activated by 5 s voltage steps from –80 mV to
potentials ranging from –100 to +40 mV in 10 mV increments
followed by a 2 s step to –120 mV in the absence (fig. 2, left panel)
and presence (fig. 2, middle panel) of (S)-2. For current-voltage (I-
V) curves, the steady state current was measured and plotted
against the corresponding potential (fig. 2, right panel). On Kv7.1
application of (S)-2 led to a small but significant reduction in
current at 220 mV and above (P,0.01, n=10) (fig. 2A). The
current amplitude at +40 mV in the presence of (S)-2 was
87.962.2% of control. On Kv7.2 channels (S)-2 exerted opposite
effects on current amplitude at high and low voltages with
the effect crossing over from positive to negative at –20 mV
( f i g .2 B ) .A t– 4 0m Vt h ec u r r e n tw a s2 0 8 . 7 622.2% of control,
while at +40 mV the current amplitude was 87.562.6% of
control (n=16). A similar effect was observed on heteromeric
Kv7.2/3 channels (fig. 2C), where the current amplitude
was 182.6616.2% and 82.961.9% of control at –40 mV and
+40 mV, respectively (n=16). On Kv7.4 (fig. 2D) and
Kv7.5 (fig. 2E) (S)-2 induced a profound increase in current
amplitude at all potentials. The current amplitude at +40 mV was
1926.96259.5% of control for Kv7.4 (n=10) and 676.0683.5%
of control for Kv7.5 (n=6).
Effect of (S)-2 on Voltage-Dependence of Activation
The I-V curves showed a negative shift in the threshold for
activation for the neuronal Kv7 channels upon (S)-2 application.
To analyze the voltage-dependence of Kv7.1-5 activation, the tail-
current measured after repolarization to –120 mV was normalized
to extend from 0 to 1, plotted as a function of the preceding
potential and fitted to a Boltzmann equation (Eq. 1, fig. 3). Under
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8251Figure 2. Activation of Kv7 channels by (S)-2. Representative two-electrode voltage-clamp current traces in the absence (left) and presence
(middle) of 10 mM (S)-2 and effect of (S)-2 on current-voltage (I-V) relationship (right) of Kv7.1 (A), Kv7.2 (B), Kv7.2/Kv7.3 (C), Kv7.4 (D) and Kv7.5 (E)
channels expressed in Xenopus laevis oocytes. The channels were activated by 5 s voltage steps from 280 mV to potentials ranging from –100 to
+40 mV in 10 mV increments followed by a 2 S step to –120 mV. The steady state peak current amplitudes in the absence and presence of 10 mM (S)-
2 were normalized against the current at +40 mV in control recordings and plotted against the test potential to obtain I-V curves (left). Bars represent
S.E.M. and n=6-17. Please note that in some instances the S.E.M. is so small that the error bars are not visible.
doi:10.1371/journal.pone.0008251.g002
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dependent activation with half-maximal activation (V0.5)o f
–18.061.6 mV. Application of (S)-2 did not result in a change
of voltage-dependence (V0.5 with (S)-2: 16.061.4 mV, P=0.4,
n=11). The voltage-dependence of activation of Kv7.2 (fig. 3B)
was shifted significantly in the hyperpolarized direction by (S)-2
with a shift in V0.5 of 19.0 mV from –27.362.4 to –46.365.1 mV
(P=0.003, n=10). Heteromeric Kv7.2/3 channels (fig. 3C)
demonstrated a similar leftward shift in voltage-dependence after
application of (S)-2 with a change in V0.5 of 18.0 mV from
–26.462.3 mV to –44.465.6 mV (P,0.02, n=5). The largest
shift in V0.5 was observed for Kv7.4 (fig. 3D) where application of
(S)-2 led to negative shift of 30.4 mV from –0.663.5 to
–31.063.8 mV (P,0.0001, n=11). For Kv7.5 (fig. 3E) there
was a leftward shift in V0.5 of 18.1 mV from –25.162.6 mV to
–43.262.4 mV (P=0.0009, n=5). Because of the great disparity
between the effect of (S)-2 on the I-V relationship of Kv7.2 and
Kv7.4, we continued with a more detailed examination of the
effects on these two subtypes.
Potency of (S)-2 on Kv7.2 and Kv7.4
To determine the potency of (S)-2 on Kv7.2 and Kv7.4 we
performed a dose-response experiment using an
86Rb-flux assay.
CHO cells expressing Kv7.2 or Kv7.4 were stimulated with
increasing concentrations of (S)-2 and the normalized efflux of
86Rb was plotted against the corresponding drug concentration.
Kv7.2 was activated by the compound with an EC50 of 0.17 mM
(pEC50=6.7760.05 M, n=6, fig. 4A) corresponding well with
the 0.06 mM reported previously [19]. Kv7.4 was activated by
( S ) - 2w i t ha nE C 50 of 0.22 mM( p E C 50=6.6660.11 M, n=8,
fig. 4B).
Effect of (S)-2 on Resting Membrane Potential
Expression of Kv7 channels in oocytes leads to a hyperpolar-
ization of the oocytes to membrane potentials that lie close to the
activation threshold of the channels. For example, oocytes that
express Kv7.2/3 have a membrane potential of approximately
260 mV, which corresponds to the threshold for activation of
Kv7.2/3. Application of retigabine leads to a further hyperpolar-
ization of the membrane potential to a potential that corresponds
to the activation threshold for the channel in the presence of
retigabine [17]. We studied the effect of (S)-2 on the membrane
potential of oocytes expressing either Kv7.2 or Kv7.4 using
membrane potential recordings (data not shown). Oocytes
expressing Kv7.2 had an average resting membrane potential of
–54.361.2 mV. Application of 10 mM (S)-2 led to a rapid and
significant hyperpolarization of the membrane potential to an
average of –82.861.5 mV (P,0.001, n=12). Similarly, applica-
tion of (S)-2 to oocytes expressing Kv7.4 led to a ,32 mV
hyperpolarization of the membrane potential from –38.862.2 mV
to –70.662.1 mV (P,0.001, n=9).
Effect of (S)-2 on Kv7 Channel Kinetics
From the current traces in figure 2 it is obvious that (S)-2
affected the kinetics of the neuronal Kv7 channels, most evidently
the deactivation. To examine and quantify this further we
calculated the time constants for activation and deactivation of
Kv7.2 and Kv7.4 in the absence and presence of (S)-2. For Kv7.2
activation traces recorded after stepping from 280 mV to
potentials between 240 mV and +40 mV were best fitted to a
double exponential function (Eq. 2) that gives separate time
constants for the slow and the fast component of the activation.
Both the fast and the slow component of the activation kinetics for
Figure 3. Effect of (S)-2 on the voltage-dependence of activation. Tail currents measured for Kv7.1 (A), Kv7.2 (B), Kv7.2/Kv7.3 (C), Kv7.4 (D)
and Kv7.5 (E) after stepping back to 2120 mV from 5 s long potentials between –100 and +60 mV were normalized and plotted against the
preceding potential in the absence and presence of 10 mM (S)-2. The tail current-voltage relationship was then fitted to the Boltzmann equation (Eq.
1) to yield half-activation potentials (V0.5). Bars represent S.E.M. and n=5–11.
doi:10.1371/journal.pone.0008251.g003
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slow activation at 240 mV (tfast=375.7631.8 ms and tslow=
1792.56162.0 ms, n=13) and accelerated activation at more
depolarized potentials (tfast=37.665.7 ms and tslow=149.16
11.8 ms at +40 mV, n=13, fig. 5A and B). In the presence of
(S)-2 the fast component of the activation was still voltage-
dependent but the time course was significantly accelerated
(tfast=196.5613.8 ms at 240 mV, P,0.001 and 25.561.8 ms
at +40 mV, P,0.01, n=10–13). Similar to how (S)-2 affected the
current amplitude of Kv7.2, there was a cross-over in the effect on
the slow component of the activation, here observed at around
210 mV. Below this voltage tslow was significantly decreased
(tslow=942.1662.6 ms at 240 mV, n=10–13, P,0.001) while it
was significantly increased at potentials above 0 (tslow=557.76
124.3 ms at +40 mV, P,0.01).
The activation traces recorded for Kv7.4 between 220 and
+60 mV were best fitted to a single exponential function (Eq. 3). In
the absence of drug the activation kinetics of Kv7.4 were slightly
voltage-dependent with slower time course of activation at
higher potentials ranging from 419.3634.6 ms at –20 mV to
636.3645.6 ms at +60 mV (n=8, fig. 5C). In the presence of (S)-2
the activation kinetics became significantly accelerated and were
largely voltage-independent with activation time constants of
286.3622.5 ms at –20 mV (n=8,P,0.05) and 278.9624.4 ms at
+60 mV (n=8,P,0.001).
Deactivation kinetics were studied using a voltage-clamp
protocol that comprised a 5 s activation step to +40 mV followed
by a 6 s test pulse to potentials between 2110 mV and 280 mV.
The deactivation traces were best fitted to a double exponential
function (Eq. 2) for both Kv7.2 and Kv7.4. For Kv7.2 we did not
observe a clear inward tail current after a step from +40 mV to
280 mV and this potential was therefore excluded. Normalized
traces illustrating the effect of (S)-2 on the deactivation kinetics of
Kv7.2 at 2110, 2100 and 290 mV is shown in fig. 6A. The time
constants for the fast and the slow component of the deactivation
for Kv7.2 in the absence and presence of (S)-2 are listed in table 1.
(S)-2 significantly slowed both the fast and the slow component of
the deactivation (fig. 6B and C). In addition, the compound
significantly increased the relative contribution of the slow
component at all potentials tested (fig. 6D).
Normalized traces illustrating the effect of (S)-2 on the
deactivation kinetics of Kv7.4 is shown in fig. 6E. The time
constants for the fast component of deactivation for Kv7.4 I
the absence and presence of (S)-2 are listed in table 1. (S)-2




Figure 5. Effect of (S)-2 on the activation kinetics of Kv7.2 and Kv7.4. For determination of activation kinetics, current traces recorded during
5 s voltage steps from –80 mV to potentials between –40 and +40 mV for Kv7.2 in the absence and presence of (S)-2 were fitted to a double
exponential function and the time constants tfast (A) and tslow (B) obtained were plotted against the step potential. For Kv7.4 current traces recorded
during 5 s voltage steps to potentials between –20 and +60 mV were fitted to a single exponential function and t is plotted against the step
potential (C). Asterisks indicate statistical significant difference between absence and presence of (S)-2 determined by two-way ANOVA followed by
Bonferroni post-test. * P,0.05, ** P,0.01 and *** P,0.001. Bars represent S.E.M. and n=8-13.
doi:10.1371/journal.pone.0008251.g005
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2110 mV and 2100 mV the traces could no longer be fitted
satisfactorily to an exponential function and instead showed an
almost linear relationship. At 290 and 280 mV where satisfac-
tory fits could be obtained both tfast and tslow were significantly
increase (fig. 6F and G). This was accompanied by a dramatic
increase in the relative contribution of the slow component of
deactivation from ,20% to ,90% (fig. 6H).
(S)-2 Affects the Inactivation of Kv7.4
Although the M-current traditionally is described as non-
inactivating, Kv7.4 and Kv7.5 have recently been found to
inactivate [21,22]. This inactivation can be modulated by
chemical compounds like BMS-204352 [21]. To study the effect
of (S)-2 on inactivation of Kv7.4 oocytes were clamped for 20 s
at potentials between 2120 mV and +60 mV in 20 mV
increments. This step was followed by a 5 s activation step to
+40mV and ended by a 5 s step to –30 mV. The peak current
after the step to +40 mV was plotted against the preceding
potential (Vpre) and normalized to the peak current measured
after a Vpre of –120 mV. This revealed a voltage-dependent
inactivation for Kv7.4 with a maximal inactivation of
65.163.6% after a Vpre of +60 mV (n=11, fig. 7A and C),
which corresponds well with our previous results [21]. Applica-
tion of (S)-2 resulted in a complete change in the inactivation
properties of Kv7.4 with almost no inactivation at negative Vpre
potentials and a maximal inactivation of 22.964.2% after a Vpre
to +60 mV (n=14, fig. 7B and C).
Figure 6. Effect of (S)-2 on the deactivation kinetics of Kv7.2 and Kv7.4. Normalized tail current traces for Kv7.2 (A) and Kv7.4 (E) obtained at
the indicated potentials in the absence and presence of (S)-2 illustrating the pronounced effect of the compound on the deactivation kinetics.
Deactivation kinetics for Kv7.2 were determined by fitting the tail currents measured at potentials between –110 mV and –90 mV after an activating
step to +40 mV to a double exponential function. The time constants tfast (B) and tslow (C) were plotted against the potential. (D) Relative
contribution of the slow component of the deactivation kinetics for Kv7.2. Tail currents measured between 2110 and 280 mV for Kv7.4 were fitted
to a double exponential function and tfast (F) and tslow (G) were plotted against the potential. (H) Relative contribution of the slow component of the
deactivation kinetics for Kv7.4. Asterisks indicate statistical significant difference between absence and presence of (S)-2 determined by two-way
ANOVA followed by Bonferroni post-test. * P,0.05, ** P,0.01 and *** P,0.001. Bars represent S.E.M. and n=5–14.
doi:10.1371/journal.pone.0008251.g006
Table 1. Deactivation kinetics.
V[mV] tslow [ms] tslow [ms] tfast [ms] tfast [ms] Islow/(Islow+Ifast)I slow/(Islow+Ifast)
(S)-2 2 + 2 + 2 +
Kv7.2 2110 526.5650.4 (n=10) 1054.3684.6 *** (n=14) 61.264.8 (n=10) 228.2623.1 *** (n=14) 27.662.8% (n=10) 52.365.2% *** (n=14)
2100 646.0693.4 (n=14) 1047.3662.5 * (n=14) 72.868.3 (n=14) 201.2617.2 *** (n=14) 27.563.1% (n=14) 57.962.3% *** (n=14)
290 642.3662.2 (n=12) 935.06118.5 ** (n=14) 106.767.1 (n=12) 165.8611.0 ** (n=14) 33.063.4% (n=12) 64.863.3% *** (n=14)
Kv7.4 2110 231.4614.4 (n=9) n.d., see text 18.361.0 (n=9) n.d., see text 19.263.0% (n=9) n.d., see text
2100 276.6622.3 (n=10) n.d., see text 24.961.7 (n=10) n.d., see text 17.562.8% (n=10) n.d., see text
290 308.5623.6 (n=10) 1320.66176.4 *** (n=5) 35.663.1 (n=10) 107.8628.5 *** (n=5) 21.363.2% (n=10) 93.060.7% *** (n=5)
280 350.3625.7 (n=8) 1309.06149.0 *** (n=6) 49.064.2 (n=8) 124.3616.9 *** (n=6) 25.062.9% (n=8) 88.861.3% *** (n=6)
Asterisks indicate statistical significant difference between absence and presence of (S)-2 determined by two-way ANOVA followed by Bonferroni post-test.
*P,0.05,
**P,0.01 and *** P,0.001.
doi:10.1371/journal.pone.0008251.t001
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Activation of Kv7.2-5 by retigabine is critically dependent on a
conserved tryptophan residue in S5 of the channels [23,24]. This
residue has also been found to be part of the binding sites for
B M S - 2 0 4 3 5 2a n d( S ) - 1[ 2 0 ]a n dh a sb e e ns u g g e s t e dt ob eam a j o r
structural element of a more common Kv7 channel activator site.
We investigated if the effect of (S)-2 also is dependent on this
residue by substituting the tryptophan residue in Kv7.2 and
Kv7.4 with a leucine. The resulting mutant channels, Kv7.2-
W236L and Kv7.4-W242L, were then expressed in oocytes and
exposed to (S)-2. For Kv7.4 the mutation resulted in a complete
loss of sensitivity to (S)-2 (fig. 8A–C). Surprisingly, Kv7.2-W236L
remained sensitive to (S)-2, but instead of activating the channel
the compound induced a significant reduction in current
amplitude at potentials from –20 mV and above (P,0.01,
n=10, fig. 8D and E). The current amplitude at +40 mV in the
presence of (S)-2 was 76.663.2% of control. (S)-2 had no effect on
the voltage-dependence of activation for either mutant (data not
shown).
The inhibitory action of (S)-2 on Kv7.2-W236L was further
analyzed by performing a dose-response experiment using an
86Rb-flux assay (fig. 8F). CHO cells expressing Kv7.2-W236L
were stimulated with buffer containing 30 mM K
+ (to activate the
channels) in the presence of concentrations of (S)-2 between
0.024 mM and 100 mM. The normalized efflux of
86Rb was
plotted against (S)-2 concentration and fitted to the Hill equation
(Eq. 4). (S)-2 dose-dependently inhibited the efflux through Kv7.2-
W236L with an IC50 of 8.1 mM (pIC50: 5.160.1 M, n=4).
As seen in fig. 8A (S)-2 affected the activation kinetics of the
mutated Kv7.2, hence we calculated activation time constants for
the current traces at potentials between 240 mV and +40 mV
(fig. 8G and H). Like for the WT Kv7.2 the activation traces of
Kv7.2-W236L were best fitted to a double exponential function
(Eq. 2). (S)-2 did not affect the fast component of the activation
(tfast=237.8626.7 ms at –40 mV and 33.661.7 ms at +40 mV in
the absence of drug and 216.0617.2 ms at –40 mV and
40.961.0 ms at +40 mV in the presence of (S)-2, n=7, P=0.89)
but significantly increased the slow component at all potentials
tested (P,0.05–P,0.001, n=7). The tslow at +40 mV was
288.0633.3 ms and 664.8671.8 ms in the absence and presence
of (S)-2, respectively. The deactivation kinetics of Kv7.2-W236L
were not affected by (S)-2 (data not shown).
(S)-2 Sensitivity of Heteromeric Kv7.4/Kv7.4-W242L
Channels
Retigabine is proposed to be dependent on the critical
tryptophan residue being present in all four subunits of a channel
complex to exert its effects [24]. To address whether this is also the
case for (S)-2 we co-expressed WT Kv7.4 and Kv7.4-W242L in a
ratio of 1:1 in oocytes. If the activity of (S)-2 was dependent on it
being bound to all four subunits, we would expect the increase in
current after application of (S)-2 to correspond to the population of
homomeric Kv7.4 channels present. Assuming random assembly,
the binomial distribution predicts this population to be 6.25% of
the total. As seen in figure 9A, the increase in current after
exposure of oocytes co-expressing WT and mutated Kv7.4
Figure 7. Effect of (S)-2 on the inactivation of Kv7.4. Representative two-electrode voltage-clamp recordings elicited by the voltage protocol
shown in the inset in the absence (A) and presence (B) of 10 mM (S)-2. (C) The degree of inactivation in the absence and presence of (S)-2 is revealed
by plotting the current amplitude measured at +40 mV normalized to the level measured after a prepulse potential of –120 mV as a function of the
preceding prepulse potential. Bars represent S.E.M. and n=11–14.
doi:10.1371/journal.pone.0008251.g007
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solely as an effect of the compound on the small percentage of
pure WT channels that would be present. Both the increase in
current amplitude (1158.16147.9% of control for Kv7.4 and
587.16147.9% of control for Kv7.4/Kv7.4-W242L at +40 mV)
and the shift in V0.5 (235.6 mV for Kv7.4 and –19.1 mV for
Kv7.4/Kv7.4-W242L) was approximately half of that observed
when stimulating homomeric Kv7.4 with 15 mM (S)-2 (fig. 9A and
B). An explanation for these observations could be that the WT
and W242L mutant subunits were not forming heteromers. To test
this we co-expressed Kv7.4-W242L with the dominant negative
pore mutant Kv7.4-G285S [8]. Oocytes co-expressing Kv7.4-
W242L and Kv7.4-G285S did not give rise to any measurable
current (data not shown), suggesting assembly of the two mutants.
We concluded that the W242L mutant was capable of forming
heteromers with WT subunits.
To test whether the effect of implementing mutated subunits in
the channel complex was to reduce the potency of the compound
we compared dose-response curves of (S)-2 on homomeric Kv7.4
and heteromeric Kv7.4/Kv7.4-W242L channels (fig. 9C). Such a
reduction in potency could imply that the compound bound in a
cooperative fashion, i.e. binding to one subunit would facilitate the
binding to another. These experiments showed that the presence
of Kv7.4-W242L subunits does not change the compound’s
potency. The EC50 values for homomeric Kv7.4 and heteromeric
Kv7.4/Kv7.4-W242L channels were 0.35 mM (pEC50=6.456
0.09 M) and 0.66 mM (pEC50=6.1860.04 M), respectively
(n=8). Although there was a statistically significant difference
between the pEC50 values (P=0.01) the difference is likely too
small to be of importance. There was no significant difference
between the Hill coefficient for (S)-2 on homomeric Kv7.4 and
heteromeric Kv7.4/Kv7.4-W242L channels (1.6860.3 for Kv7.4
Figure 8. Dependency of (S)-2 on a tryptophan residue in S5. Representative two-electrode voltage-clamp current traces of Kv7.4-W242L (A)
and Kv7.2-W236L (D) in the absence (left) and presence (right) of 10 mM (S)-2. Currents were elicited by 5 s depolarizing pulses between 2100 and
+40 mV in 10 mV increments from a holding potential of –80 mV followed by a 2 s step to –120 mV. The steady state peak current amplitudes of
Kv7.4-W242L (B) and Kv7.2-W236L (E) in the absence and presence of 10 mM (S)-2 were normalized against the current at +40 mV in control
recordings and plotted against the test potential to obtain current-voltage (I-V) curves (n=10). (C) Cells expressing Kv7.4-W242L were investigated for
inactivation by the same voltage protocol as in fig. 7. The plot shows the current amplitude measured at +40 mV normalized to the level measured
after a prepulse potential of –120 mV as a function of the preceding prepulse potential, n=11. (F) Dose-response relationship of the effect of (S)-2 on
Kv7.2-W236L measured using a Rubidium-flux assay (n=4). Effect of (S)-2 on the fast (G) and slow (H) components of the activation kinetics of Kv7.2-
W236L. Current traces recorded during voltage steps from –80 mV to potentials between –40 and +40 mV in the absence and presence of (S)-2 were
fitted to a double exponential function and the time constants tfast and tslow obtained were plotted against the step potential (n=7). * P,0.05,
** P,0.01 *** P,0.001 determined by two-way ANOVA followed by Bonferroni post-test. Bars represent S.E.M.
doi:10.1371/journal.pone.0008251.g008
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change in cooperativity.
Discussion
Because of the important role Kv7 channels play in controlling
electrical homeostasis in the brain, increasing Kv7 channel activity
will generally reduce neuronal excitability. Since the identification
of the Kv7 channels in the late 1990’s, several compounds have
been described as openers or inhibitors of the channels. However,
only a few of these compounds have yet earned a thorough
examination.
The acrylamide (S)-2 has previously been described as a potent
opener of murine Kv7.2 channels and has demonstrated
significant activity in reducing neuronal hyperexcitability in rat
hippocampal slices [19]. Here we show that (S)-2 activates human
homomeric Kv7.2-5 and heteromeric Kv7.2/3 channels expressed
in Xenopus laevis oocytes. In contrast to the effect on the neuronal
Kv7 channels (S)-2 weakly inhibits homomeric Kv7.1 channels. As
Kv7.1 together with KCNE1 constitutes the molecular correlate of
the slow repolarising current in the heart (the IKs current), this
observation could indicate safety liability and potential for
inducing torsades de pointes [25]. Yet, several Kv7.1 channel
active compounds exhibit markedly reduced activity when Kv7.1
is co-expressed with KCNE1 [20,26,27]. This, however, remains
to be tested for (S)-2.
Similar to most Kv7 channel openers described, (S)-2 affected
the kinetics of the channels, although the effect was different from
that of other compounds [17,20,28,29]. Interestingly, as with the
effect of the compound on the current amplitude of Kv7.2 there
was a crossover in the effect of (S)-2 on tslow resulting in a
significant increase in this time constant at more positive
potentials. This could indicate that the two effects are related
and that the reduction in current amplitude at high potentials
results from an increase in tslow. For Kv7.4, which exhibited
monoexponential activation kinetics, t was significantly reduced in
the presence of (S)-2 at all potentials tested.
Application of (S)-2 resulted in large effects on deactivation
kinetics of Kv7.2. Intriguingly, for Kv7.4, the effect of (S)-2 on
deactivation kinetics was more dramatic increasing both tfast and
Figure 9. Sensitivity of heteromeric Kv7.4/Kv7.4-W242L channels to (S)-2. (A) Current-voltage (I-V) relationship of Kv7.4 and Kv7.4/Kv7.4-
W242L in the absence and presence of 15 mM (S)-2. The steady state peak current measured at potentials between –100 and +40 mV were
normalized against the current at +40 mV in control recordings and plotted against the test potential. (B) Effect of (S)-2 on the voltage-dependence
of activation of Kv7.4 and Kv7.4/Kv7.4-W242L. Tail currents measured after stepping back to –120 mV from potentials between –100 and +60 mV in
the absence and presence of 15 mM (S)-2 were normalized and plotted against the preceding potential. The tail current-voltage relationship was then
fitted to the Boltzmann equation to yield half-activation potentials (V0.5): Kv7.4 (5.161.3 mV); Kv7.4+(S)-2 (230.561.6 mV); Kv7.4/Kv7.4-W242L
(4.161.6 mV); Kv7.4/Kv7.4-W242L+(S)-2 (215.061.0 mV). (C) Dose-response relationship of (S)-2 on Kv7.4 and Kv7.4-W242L. The steady state peak
currents elicited by a 5 s step to 0 mV in response to increasing concentrations of (S)-2 were normalized to the current in the absence of compound
and plotted as a function of the concentration of (S)-2. The values were then analyzed by non-linear regression to fit a sigmoidal curve. The EC50
values were determined to 0.46 mM and 0.72 mM and the Hill coefficients to 1.3260.17 and 1.2460.25 for Kv7.4 and Kv7.4/Kv7.4-W242L, respectively.
Bars represent S.E.M. and n=6–10.
doi:10.1371/journal.pone.0008251.g009
Kv7 Channel Modulation
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8251tslow and strikingly changing the contribution of the slow
component of the deactivation kinetics. Notably, at some
potentials the deactivation was not only slowed but the kinetic
mode was completely altered. Slowing of deactivation may have
profound effects on cellular excitability, as the channels with (S)-2
bound will remain open for a longer period each time they are
activated. Hence, (S)-2 appears especially well suited for further
studies of the impact of Kv7 channel deactivation rates on various
physiological parameters.
Inactivation has recently been described as a new regulatory
mechanism for Kv7.4 and Kv7.5 [21,22]. At physiologically
relevant membrane potentials, the current is reduced by more
than 30% due to steady-state inactivation. We found that (S)-2
reduced the inactivation of Kv7.4. One consequence of reduced
inactivation would be increased current amplitudes; however, the
effect of (S)-2 on the current amplitude of Kv7.4 was much larger
than what can be accounted for by reduced inactivation alone.
There is evidence indicating that Kv7 channels only display one
conductance level [30–33]. Neither of the drugs which effect has
been examined at the single-channel level alters the conductance
of the channels but instead increases the open probability [31–33].
It is likely that (S)-2 also works by increasing the open probability
of the neuronal Kv7 channels.
A conserved tryptophan residue within the fifth transmembrane
segment of Kv7.2-5 is a structural element of a major binding site
in the neuronal Kv7 channels. Retigabine, BMS-204352 and (S)-1
are all dependent on the residue for their effects [20,23,24].
Interestingly, all of these tryptophan-dependent compounds
behave similarly regarding effects on current amplitude and
voltage-dependence of activation, albeit with different potency and
efficacy. Recently, several groups indicated that Zink pyrithione,
meclofenamic acid and diclofenac recognize other binding sites
[28,33,34].
We found that (S)-2 also is dependent on the tryptophan residue
for its enhancing effect, indicating an overlapping pharmacophore
with retigabine. However, it is likely that besides the tryptophan
residue, (S)-2 interacts with other residues than retigabine, as (S)-2
modulates the inactivation of Kv7.4, an ability retigabine does not
possess [21]. The inactivation of the Kv7.4-W242L mutant was
not affected by (S)-2, indicating that the integrity of the whole
pharmacophore is crucial also for (S)-2 modulation of inactivation.
Intriguingly, substitution of the tryptophan residue in Kv7.2
with leucine (Kv7.2-W236L) produced a channel that was
inhibited by (S)-2 seen as a reduction in current amplitude
without affecting the voltage-dependence of activation. In
addition, the slow time constant of activation was increased. We
propose that the mechanism behind this inhibition is the same as
for the secondary inhibitory action of (S)-2 observed on the current
amplitude and tslow of WT Kv7.2. In fact, plotting the current
amplitude of Kv7.2 and Kv7.2-W236L in the presence of (S)-2
against the voltage above their resulting threshold yields two
superimposed curves. Hence, considering the (S)-2-induced shift in
voltage-dependence of activation, it can be argued that (S)-2
decreases the current amplitude of Kv7.2 at all potentials relative
to the threshold of activation. The effect of (S)-2 on Kv7.2 may
thereby be divided into two entities; an activating part visible as
shift in voltage-dependence of activation and an inhibitory part
visible as a decrease in current amplitude and an increase in tslow.
Apparently, the W236L mutation only disables the (S)-2-induced
activation, thereby unmasking the inhibitory component of the
drug effect. Since inhibition requires higher concentrations than
activation (fig. 4A vs. fig. 8F) it is likely that these effects rely upon
action at different interactions sites, as has been suggested for the
secondary inhibitory effect of retigabine [18,24,31]. It is also
possible that the activating and inhibitory effects are consequences
of the compound binding in two different conformations to an
overlapping site. Interestingly, Kv7.4-W242L was not inhibited by
(S)-2, indicating a degree of subtype selectivity.
It has been demonstrated that four tryptophan residues within a
tetramer are necessary for activation of Kv7 channels by
retigabine [24]. We present data indicating that this may not be
the case for the activation of Kv7 channels by (S)-2. Our results do
not fit to a model where the channel responds to (S)-2 in an ‘‘all-
or-non’’ fashion. One plausible explanation is that the effect of (S)-
2 is proportional to the number of subunits that are occupied by
the compound. To assess our hypothesis the effect of (S)-2 on each
stoichiometry of heteromeric Kv7.4/Kv7.4-W242L channels
needs to be determined at the single-channel level. Albeit, this
approach is hampered by the low open probability of Kv7.4
channels [32].
In conclusion, (S)-2 is a modulator of Kv7 channels with
differential effects on the channel subtypes. We present data
revealing that the consequence of binding is not purely activating
for all neuronal subtypes, suggesting the existence of a subtype
specific additional inhibitory binding site or a mode of binding not
dependent on the described tryptophan residue. Improved
understanding of those molecular determinants may contribute
to the design of subtype selective channel modulators. Further-
more, our pharmacological profiling suggests that (S)-2 is a suitable
tool complementing retigabine in the study of Kv7 channels.
Acknowledgments
Part of this work was presented at the 6
th FENS Forum of European
Neuroscience. We thank Bo Hjorth Bentzen for critically reading the
manuscript.
Author Contributions
Conceived and designed the experiments: SMB NS HSJ. Performed the
experiments: SMB. Analyzed the data: SMB HSJ. Contributed reagents/
materials/analysis tools: NS HSJ. Wrote the paper: SMB NS HSJ.
References
1. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, et al. (1996)
KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium
current. Nature 384: 78–80.
2. Sanguinetti MC, Curran ME, Zou A, Shen J, Specter PS, et al. (1996)
Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS
potassium channel. Nature 384: 80–83.
3. Robbins J (2001) KCNQ potassium channels: physiology, pathophysiology, and
pharmacology. Pharmacol Therapeut 90: 1–19.
4. Mackie AR, Byron KL (2008) Cardiovascular KCNQ (Kv7) Potassium
Channels: Physiological Regulators and New Targets for Therapeutic
Intervention. Mol Pharmacol 74: 1171–1179.
5. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, et al. (1998) KCNQ2 and
KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel.
Science 282: 1890–1893.
6. Jentsch TJ (2000) Neuronal KCNQ potassium channels:physislogy and role in
disease. Nat Rev Neurosci 1: 21–30.
7. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, et al. (1998) KCNQ2 and
KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel.
Science 282: 1890–1893.
8. Kubisch C, Schroeder BC, Friedrich T, Lu ¨tjohann B, El-Amraoui A, et al.
(1999) KCNQ4, a Novel Potassium Channel Expressed in Sensory Outer Hair
Cells, Is Mutated in Dominant Deafness. Cell 96: 437–446.
9. Selyanko AA, Hadley JK, Wood IC, Abogadie FC, Jentsch TJ, et al. (2000)
Inhibition of KCNQ1-4 potassium channels expressed in mammalian cells via
M1 muscarinic acetylcholine receptors. J Physiol 522 Pt 3: 349–355.
10. Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ (2000)
KCNQ5, a Novel Potassium Channel Broadly Expressed in Brain, Mediates M-
type Currents. J Biol Chem 275: 24089–24095.
Kv7 Channel Modulation
PLoS ONE | www.plosone.org 11 December 2009 | Volume 4 | Issue 12 | e825111. Lerche C, Scherer CR, Seebohm G, Derst C, Wei AD, et al. (2000) Molecular
cloning and functional expression of KCNQ5, a potassium channel subunit that
may contribute to neuronal M-current diversity. J Biol Chem 275:
22395–22400.
12. Cooper EC, Harrington E, Jan YN, Jan LY (2001) M Channel KCNQ2
Subunits Are Localized to Key Sites for Control of Neuronal Network
Oscillations and Synchronization in Mouse Brain. J Neurosci 21: 9529–9540.
13. Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El-Amraoui A, et al.
(2000) From the Cover: KCNQ4, a K+ channel mutated in a form of dominant
deafness, is expressed in the inner ear and the central auditory pathway. Proc
Natl Acad Sci U S A 97: 4333–4338.
14. Martire M, D’Amico M, Panza E, Miceli F, Viggiano D, et al. (2007)
Involvement of KCNQ2 subunits in [3H]dopamine release triggered by
depolarization and pre-synaptic muscarinic receptor activation from rat striatal
synaptosomes. J Neurochem 102: 179–193.
15. Hansen HH, Ebbesen C, Mathiesen C, Weikop P, Ronn LC, et al. (2006) The
KCNQ Channel Opener Retigabine Inhibits the Activity of Mesencephalic
Dopaminergic Systems of the Rat. J Pharmacol Exp Ther 318: 1006–1019.
16. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK (2000) Retigabine, A
Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium
Channels. Mol Pharmacol 58: 591–600.
17. Main MJ, Cryan JE, Dupere JRB, Cox B, Clare JJ, et al. (2000) Modulation of
KCNQ2/3 Potassium Channels by the Novel Anticonvulsant Retigabine. Mol
Pharmacol 58: 253–262.
18. Tatulian L, Delmas P, Abogadie FC, Brown DA (2001) Activation of Expressed
KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents
by the Anti-Convulsant Drug Retigabine. J Neurosci 21: 5535–5545.
19. Wu YJ, Boissard CG, Chen J, Fitzpatrick W, Gao Q, et al. (2004) (S)-N-[1-(4-
Cyclopropylmethyl-3,4-dihydro-2H-benzo[ and ]oxazin-6-yl)-ethyl]-3-(2-fluoro-
phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits
induced hyperexcitability of rat hippocampal neurons. Bioorg Med Chem Lett
14: 1991–1995.
20. Bentzen BH, Schmitt N, Calloe K, Dalby-Brown W, Grunnet M, et al. (2006)
The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels.
Neuropharmacology 51: 1068–1077.
21. Jensen HS, Grunnet M, Olesen SP (2007) Inactivation as a New Regulatory
Mechanism for Neuronal Kv7 Channels. Biophys J 92: 2747–2756.
22. Seebohm G, Strutz-Seebohm N, Baltaev R, Korniychuk G, Knirsch M, et al.
(2005) Regulation of KCNQ4 Potassium Channel Prepulse Dependence and
Current Amplitude by SGK1 in Xenopus oocytes. Cell Physiol Biochem 16:
255–262.
23. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H (2005) The New
Anticonvulsant Retigabine Favors Voltage-Dependent Opening of the Kv7.2
(KCNQ2) Channel by Binding to Its Activation Gate. Mol Pharmacol 67:
1009–1017.
24. Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, et al. (2005) Molecular
Determinants of KCNQ (Kv7) K+ Channel Sensitivity to the Anticonvulsant
Retigabine. J Neurosci 25: 5051–5060.
25. Towart R, Linders JTM, Hermans AN, Rohrbacher J, van der Linde HJ, et al.
(2009) Blockade of the IKs potassium channel: An overlooked cardiovascular
liability in drug safety screening? Journal of Pharmacological and Toxicological
Methods 60: 1–10.
26. Gao Z, Xiong Q, Sun H, Li M (2008) Desensitization of chemical activation by
auxiliary subunits: convergence of molecular determinants critical for augment-
ing KCNQ1 potassium channels. J Biol Chem 283: 22649–22658.
27. Wang HS, Brown BS, McKinnon D, Cohen IS (2000) Molecular basis for
differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer
XE991. Mol Pharmacol 57: 1218–1223.
28. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, et al. (2005) Meclofenamic
Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel
Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant
Properties. Mol Pharmacol 67: 1053–1066.
29. Schrøder RL, Jespersen T, Christophersen P, Strøbæk D, Jensen BS, et al. (2001)
KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacol-
ogy 40: 888–898.
30. Selyanko AA, Hadley JK, Brown DA (2001) Properties of single M-type
KCNQ2/KCNQ3 potassium channels expressed in mammalian cells. J Physiol
534: 15–24.
31. Tatulian L, Brown DA (2003) Effect of the KCNQ potassium channel opener
retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol 549:
57–63.
32. Li Y, Gamper N, Shapiro MS (2004) Single-Channel Analysis of KCNQ K+
Channels Reveals the Mechanism of Augmentation by a Cysteine-Modifying
Reagent. J Neurosci 24: 5079–5090.
33. Xiong Q, Sun H, Li M (2007) Zinc pyrithione-mediated activation of voltage-
gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol
3: 287–296.
34. Miceli F, Soldovieri MV, Martire M, Taglialatela M (2008) Molecular
pharmacology and therapeutic potential of neuronal Kv7-modulating drugs.
Curr Opin Pharmacol 8: 65–74.
Kv7 Channel Modulation
PLoS ONE | www.plosone.org 12 December 2009 | Volume 4 | Issue 12 | e8251